Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib + CHOP as First-Line Therapy in Peripheral T-Cell Lymphoma
ChiCTR2500107078Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golidocitinib in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 4 more, sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)enteropathy-associated T-cell lymphoma (EATL)monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)
Beyond the preview
Go deeper on ChiCTR2500107078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107078.